Pharmacokinetic Characterization of a Prototype Mini Nicotine Lozenge.

Plain-language guide to PMID 34105089 (2021): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 34105089
Journal: Advances in therapy
Year: 2021
Study type: Randomized Controlled Trial
Authors: Lai PM et al. (4 authors)
DOI: 10.1007/s12325-021-01798-4

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Cigarette smoking remains a substantial public health problem.

A novel prototype mini lozenge was developed to offer smokers a new NRT option to aid in their quit attempt.

Who Took Part

Heavy smokers in otherwise good health were randomly assigned to one of two treatment sequences: the prototype mini lozenge followed by a commercially available mini lozenge, or the converse.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Nothing was hidden in this open-label Therapeutic nicotine (patch, non-peptide) study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

The primary endpoint was bioequivalence as determined by maximal plasma nicotine concentration (Cmax) and the extent of nicotine absorption (AUC0-t and AUC0-∞).

The secondary endpoints included the time to Cmax (Tmax), half-life, the elimination constant (Kel), and safety.

What Was Measured

The subject headings attached to it are Nicotine, Smoking Cessation, Therapeutic Equivalency and Tobacco Use Cessation Devices.

The authors tagged it with the keywords Lozenge and Nicotine replacement therapy.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Advances in therapy), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.